How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,945 results for

Prostate Cancer Histologic grading

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

as outlined in the criteria in the NCCN ® Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ), Prostate Cancer Early Detection. Confirmed Malignancy Gene expression or molecular profiling assays for confirmed prostate tumors are not medically necessary. Thyroid Cancer Confirmed or Highly-Suspected Thyroid Cancer BRAF V600E mutation analysis is medically necessary in cases with confirmed or highly-suspected follicular thyroid carcinoma, papillary thyroid carcinoma, medullary thyroid carcinoma (...) Use Criteria 3 National Comprehensive Cancer Network® (NCCN®) Criteria* 4 Polycythemia Vera 5 Essential Thrombocythemia or Thrombocytosis 5 Primary Myelofibrosis 5 Breast Cancer 6 Cancer of Unknown Primary/Occult Neoplasm 7 Prostate Cancer 7 Screening 7 Confirmed Malignancy 7 Thyroid Cancer 7 Confirmed or Highly-Suspected Thyroid Cancer 7 Cytologically Indeterminate Thyroid Nodule 7 Colorectal Cancer Screening 8 CPT Codes 8 Background 12 Myeloproliferative Disorders 12 Polycythemia Vera 12

2019 AIM Specialty Health

2. Management of Female Malignant Ovarian Germ Cell Tumours

will be cured with chemotherapy at recurrence. 24,25 At present, there are insufficient data to recommend that women with stage Ic disease be offered surgery followed by surveillance alone. However, women with immature grade I or II teratomas could probably be considered for surveillance. Whether this would also be safe for women with stage Ic grade III disease, which frankly should be viewed as a malignant tumour that has not been completely © Royal College of Obstetricians and Gynaecologists 3 of 10 (...) treatment Women who have residual masses at completion of chemotherapy should be offered resection even if the tumour markers are normal. 41 This is to exclude residual disease or any residual mature teratoma which can progress as mature teratoma growing syndrome in up to 30% of cases, and more rarely, over time, undergo malignant transformation into an incurable tumour type, such as squamous carcinoma. Early recognition of this syndrome is essential as it offers hope for curative resection and avoids

2016 Royal College of Obstetricians and Gynaecologists

3. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma). (Abstract)

PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma). The loss of PTEN tumor suppressor gene is one of the most common somatic genetic aberrations in prostate cancer (PCa) and is frequently associated with high-risk disease. Deletion or mutation of at least one PTEN allele has been reported to occur in 20% to 40% of localized PCa and up to 60% of metastases. The goal (...) of this study was to determine if somatic alteration detected by PTEN immunohistochemical loss of expression is associated with specific histologic features.Two hundred sixty prostate core needle biopsies with PCa were assessed for PTEN loss using an analytically validated immunohistochemical assay. Blinded to PTEN status, each tumor was assessed for the Grade Group (GG) and the presence or absence of nine epithelial features. Presence of stromogenic PCa was also assessed and defined as grade 3 reactive

2019 Prostate

4. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

, Inc. All Rights Reserved. 14 Cancer of Unknown Primary/Occult Neoplasm Occult neoplasms, or cancers of unknown primary, are defined as histologically proven metastatic malignant tumors whose primary site cannot be identified during pretreatment evaluation. These may have a wide clinical presentation and typically a poor prognosis. Several laboratories offer gene expression profiling or NGS tests to aid in the identification of the tissue of origin of a metastatic tumor. NCCN ® Clinical Practice (...) Tumor Testing 10 Breast Cancer 10 Lung Cancer 12 Cell-Free Tumor Testing 13 Cancer of Unknown Primary/Occult Neoplasm 14 Prostate Cancer 14 Thyroid Cancer 15 Cancer Screening 15 Indeterminate Thyroid Nodules 15 Colorectal Cancer Screening 16 Professional Society Guidelines 18 Selected References 19 Revision History 20 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved. 3 Scope This document

2017 AIM Specialty Health

5. Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms

the Committee, issued a positive opinion for granting a marketing authorisation to Tookad on 14 September 2017. 2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy = 10 years and: - Clinical stage T1c or T2a, - Gleason Score = 6, based on high-resolution biopsy strategies, - PSA = 10 ng/mL, - 3 positive cancer cores (...) were: A. To assess the impact of Tookad VTP on the rate of absence of definite cancer using patients on active surveillance as a comparison, measured as absence of any histology result definitively positive for cancer at 24 months B. To determine the difference in rate of treatment failure associated with observed progression of disease from low risk prostate cancer to moderate or higher risk prostate cancer in men who undergo Tookad VTP compared to men on active surveillance. Secondary objectives

2017 European Medicines Agency - EPARs

6. Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging. (Abstract)

Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging. 28012760 2019 04 05 2019 04 05 1527-3792 197 2S 2017 02 The Journal of urology J. Urol. Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging. S134-S139 S0022-5347(16)31652-4 10.1016/j.juro.2016.10.099 Gleason Donald F DF Mellinger George T GT Veterans Administration Cooperative Urological Research Group eng Journal Article Randomized (...) Controlled Trial 2016 12 21 United States J Urol 0376374 0022-5347 731DCA35BT Diethylstilbestrol AIM IM J Urol. 2017 Feb;197(2S):S140-S141 28010973 Adenocarcinoma mortality pathology therapy Aged Cause of Death Chemotherapy, Adjuvant methods Diethylstilbestrol therapeutic use Follow-Up Studies Humans Male Neoplasm Grading Neoplasm Staging Orchiectomy Prognosis Prospective Studies Prostate pathology Prostatectomy Prostatic Neoplasms mortality pathology therapy Survival Rate Treatment Outcome Arduino Lino

2019 The Journal of urology Controlled trial quality: uncertain

7. Synchronous Malignant Peripheral Nerve Sheath Tumor and Adenocarcinoma of the Prostate: Case Report and Literature Review Full Text available with Trip Pro

was 1 ng/mL. Radiologic examinations demonstrated a large mass, which was arising from the left peripheral lobe of the prostate. The patient underwent transrectal ultrasound-guided biopsy of the prostate which revealed a smooth muscle tumor of uncertain malignant potential. Radical retropubic prostatectomy with en bloc removal of the mass and the seminal vesicles was performed and histology demonstrated low-grade MPNST and adenocarcinoma of the prostate. To the best of our knowledge (...) Synchronous Malignant Peripheral Nerve Sheath Tumor and Adenocarcinoma of the Prostate: Case Report and Literature Review Malignant Peripheral Nerve Sheath Tumors (MPNSTs) of the prostate are extremely rare. A very unusual case of simultaneous adenocarcinoma and MPNST of the prostate is reported. A 60-year-old Caucasian male presented for annual urologic examination. Digital rectal examination revealed a painless, toughish, and asymmetrically enlarged prostate. Serum prostate-specific antigen

2016 Case reports in urology

8. Phase I Study of AZD5363 + Olaparib + Durvalumab (MEDI4736) in Patients With Advanced or Metastatic Solid Tumor Malignancies

with advanced or metastatic solid tumor malignancies. The purpose of this trial is to determine if combination treatment of drugs, Olaparib, AZD5363 and Durvalumab has beneficial effects in advanced or metastatic cancers and to determine the effects it has on patients and their cancer. Primary Objectives • To evaluate the safety and tolerability of combination treatment AZD5363 + Olaparib + Durvalumab and determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicities (DLTs), and Recommended Phase 2 (...) Dose (RP2D) for patients with advanced or metastatic solid tumor malignancies. Secondary Objectives To determine the pharmacodynamics (PDn) of combination treatment AZD5363 + Olaparib + Durvalumab in patients with advanced or metastatic solid tumor malignancies To describe anti-tumor response using immune RECIST of combination treatment AZD5363 + Olaparib + Durvalumab in patients with advanced or metastatic solid tumor malignancies Exploratory Objectives To evaluate anti-tumour response using

2018 Clinical Trials

9. Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors. (Abstract)

Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors. Recognition of Gleason pattern 4 in prostatic needle biopsies is crucial for both prognosis and therapy. Recently, it has been recommended to record percent pattern 4 when Gleason score 7 cancer is the highest grade in a case.Four hundred and five prostate needle core biopsies received for a second opinion at our institution from February-June, 2015 were (...) prospectively diagnosed with prostatic adenocarcinoma Gleason score 7 as the highest score on review by a consultant urological pathologist. Percentage of core involvement by cancer, percentage of Gleason pattern 4 per core, distribution of Gleason pattern 4 (clustered, scattered), morphology of pattern 4 (cribriform, non-cribriform), and whether the cancer was continuous or discontinuous were recorded.Better agreement was noted between the consultant and referring pathologists when pattern 4 was clustered

2017 Prostate

10. Neratinib (Nerlynx) - Breast cancer, breast neoplasms

disease-free survival DFS-DCIS disease-free survival including ductal carcinoma in situ ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EGFR epidermal growth factor receptor EQ-5D EuroQol 5-Dimension Questionnaire ER estrogen receptor ERBB erythroblastic leukemia viral oncogene homolog; also termed HER ExteNET Extended Adjuvant Treatment of Breast Cancer with Neratinib FACT-B Functional Assessment of Cancer Therapy-Breast FMO flavin-containing monooxygenase GI gastrointestinal HER human (...) Neratinib (Nerlynx) - Breast cancer, breast neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 13 July 2018 EMA/CHMP/525204/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Nerlynx International

2018 European Medicines Agency - EPARs

11. Accuracy of standardized 12-core template biopsies versus non-standardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen. (Abstract)

Accuracy of standardized 12-core template biopsies versus non-standardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen. To evaluate the effectiveness of EAU Guideline compliant transrectal ultrasound-guided 12-core prostate biopsies for detection of highly aggressive Epstein Grade 5 (Gleason Score 9-10) prostate cancer.Two hundred ninety-nine patients, treated by radical prostatectomy for prostate cancer, have been (...) of Epstein Grade 5 compared to the radical prostatectomy specimen was: Group 1: 23.0% pre-operatively and 61.5% post-operatively, Group 2: 33.3% pre-operatively and 58.3% post-operatively; and Group 3: 57.1% pre-operatively and 64.2% post-operatively.Detection rates of highly aggressive Epstein Grade 5 prostate cancer vary considerably according to the biopsy technique. EAU Guideline compliant 12-core template biopsies increase the detection rates of Epstein Grade 5 prostate cancer.© 2018 Wiley

2018 Prostate

12. Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas Full Text available with Trip Pro

Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas To summarize the research activities of the "clinical research group heavy ion therapy", funded by the German Research Foundation (DFG, KFO 214), on the impact of intrinsic tumor characteristics (grading, hypoxia) on local tumor control after carbon (12C-) ion- and photon irradiations.Three sublines of syngeneic rat prostate tumors (R3327) with various differentiation levels (highly (-H (...) with tumor grading (1.62 ± 0.11 (H) vs 2.08 ± 0.13 (HI) vs 2.30 ± 0.08 (AT1)). Large HI-tumors resulted in a marked increase of TCD50, which was increased further by 15% under hypoxic relative to oxic conditions. Noninvasive imaging, histology and molecular analyses identified hypoxia as an important radioresistance factor in photon therapy.The dose-response studies revealed a higher efficacy of 12C-ions relative to photon therapy in the investigated syngeneic tumor model. Hypoxia turned out

2017 Radiation oncology (London, England)

13. Adjuvant Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms

contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: Male Gender Based Eligibility: Yes Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Diagnosed with prostate cancer within 6 months of screening visit Metastatic disease (Any T, Any N, M1+) of any grade, stage or Prostate Specific Antigen (PSA) level. Fit to undergo (...) standard of care treatment for metastatic disease and both minimally invasive therapy and prostate radiotherapy/prostatectomy. Performance status 0-2 Histologically proven local tumour Exclusion Criteria: Patient did not undergo and/or is unable to undergo standard of care baseline imaging tests for confirmation of metastatic status (CT abdomen/pelvis AND chest Xray (or CT chest) AND radioisotope bone scan (or whole body imaging such as MRI or PET imaging as alternative to all preceding scans mentioned

2018 Clinical Trials

14. Histologic Features of Pseudohyperplastic Perineural Invasion in Prostatic Adenocarcinoma: A Mimicker of Benign Hyperplastic Glands and High-grade Prostatic Intraepithelial Neoplasia. (Abstract)

Histologic Features of Pseudohyperplastic Perineural Invasion in Prostatic Adenocarcinoma: A Mimicker of Benign Hyperplastic Glands and High-grade Prostatic Intraepithelial Neoplasia. Perineural invasion (PNI) seen in prostatic adenocarcinoma (PCa) on biopsy has both diagnostic and prognostic implications. On biopsy, PNI is 1 of the 4 pathognomonic features of PCa; it is associated with an increased risk for extraprostatic extension, and its finding can affect therapy. From January 1, 2013 (...) biopsied at our institution with this finding also included. Of the 12 cores with pseudohyperplastic PNI, the Gleason scores were 6 in 11 cores and 4+3=7 in the remaining core. In 6 cases, the only focus of PNI in the entire case was pseudohyperplastic. In 7 of the 12 foci, the central gland wrapping around the nerve appeared to "float" unattached within the surrounding gland closely resembling a benign hyperplastic gland or high-grade prostatic intraepithelial neoplasia (HGPIN). In the remaining 5

2014 American Journal of Surgical Pathology

15. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Full Text available with Trip Pro

Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) In recent times, anti-cancer treatments have focused on Fibroblast Growth Factor (FGF) and Vascular-Endothelial Growth Factor (VEGF) pathway inhibitors so as to target tumor angiogenesis and cellular proliferation. One such drug is Nintedanib; the present study evaluated the effectiveness of Nintedanib treatment against in vitro proliferation (...) of human prostate cancer (PCa) cell lines, and growth and progression of different grades of PCa lesions in pre-clinical PCa transgenic adenocarcinoma for the mouse prostate (TRAMP) model.Both androgen-independent (LNCaP) and androgen-dependent (PC3) PCa cell lines were treated with a range of Nintedanib doses for 72 h, and effect on cell growth and expression of angiogenesis associated VEGF receptors was analyzed. In pre-clinical efficacy evaluation, male TRAMP mice starting at 8 and 12 weeks of age

2017 Journal of biomedical science

16. Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. (Abstract)

Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. Histologic grading remains the gold standard for prognosis in prostate cancer, and assessment of Gleason score plays a critical role in active surveillance management. We sought to optimize the prognostic stratification of grading and developed a method of recording and studying (...) individual architectural patterns by light microscopic evaluation that is independent of standard Gleason grade. Some of the evaluated patterns are not assessed by current Gleason grading (eg, reactive stromal response). Individual histologic patterns were correlated with recurrence-free survival in a retrospective postradical prostatectomy cohort of 1275 patients represented by the highest-grade foci of carcinoma in tissue microarrays. In univariable analysis, fibromucinous rupture with varied

2016 American Journal of Surgical Pathology

17. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer

and could be considered for inclusion in the evidence base. As a second stage, the focus was on locating and evaluating primary literature not already covered in any existing systematic reviews. PubMed was used to systematically search for articles evaluating the clinical utility of germline and somatic tumor testing in ovarian cancer, again between 2007 and March 23, 2018. The search combined disease-specific terms (neoplasm, carcinoma, cancer) along with site-specific terms (ovary, ovarian) and gene (...) of PARP inhibitors, women with ovarian cancer who carry BRCA1/2 mutations have been reported to have improved PFS compared with noncarriers, regardless of tumor stage, grade, or histologic subtype. Clinical interpretation. Three PARP inhibitors (ie, niraparib, olaparib, and rucaparib) are FDA approved for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who exhibit complete or partial response to platinum-based chemotherapy

2020 American Society of Clinical Oncology Guidelines

18. Automatic stratification of prostate tumour aggressiveness using multiparametric MRI: a horizontal comparison of texture features. (Abstract)

Automatic stratification of prostate tumour aggressiveness using multiparametric MRI: a horizontal comparison of texture features. Previous studies have identified apparent diffusion coefficient (ADC) from diffusion-weighted imaging (DWI) can stratify prostate cancer into high- and low-grade disease (HG and LG, respectively). In this study, we consider the improvement of incorporating texture features (TFs) from T2-weighted (T2w) multiparametric magnetic resonance imaging (mpMRI) relative (...) to mpMRI alone to predict HG and LG disease.In vivo mpMRI was acquired from 30 patients prior to radical prostatectomy. Sequences included T2w imaging, DWI and dynamic contrast enhanced (DCE) MRI. In vivo mpMRI data were co-registered with 'ground truth' histology. Tumours were delineated on the histology with Gleason scores (GSs) and classed as HG if GS ≥ 4 + 3, or LG if GS ≤ 3 + 4. Texture features based on three statistical families, namely the grey-level co-occurrence matrix (GLCM), grey-level run

2019 Acta Oncologica

19. Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy. (Abstract)

Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy. To assess the impact of cribriform pattern and/or intraductal carcinoma (IDC) on Gleason 7 prostate cancer (PCa) treated with external beam radiotherapy (EBRT).We evaluated men with Gleason 7 (Grade Group 2 and 3) PCa treated with dose-escalated EBRT +/- androgen deprivation, and reviewed biopsies for the presence of cribriform pattern and/or IDC. Endpoints included (...) biochemical recurrence free survival (BRFS), distant metastasis free survival (DMFS), and disease specific survival (DSS).Of 237 patients, median follow up was 117 months (range 3-236), and NCCN risk group was 24% favorable-intermediate risk, 53% unfavorable-intermediate risk, and 23% high risk. Rates of cribriform pattern without IDC, cribriform pattern with IDC, IDC without cribriform pattern, and neither morphology, were 36%, 13%, 0%, and 51%, respectively. On multivariable analysis (MVA), presence

2019 Journal of Urology

20. Study of RC48-ADC in Patients With HER2-Positive Advanced Malignant Solid Tumors

Posted : January 18, 2019 See Sponsor: RemeGen Information provided by (Responsible Party): RemeGen Study Details Study Description Go to Brief Summary: A tolerance, safety and pharmacokinetic ascending dose Phase I Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive malignant in Advanced Malignant solid Tumors. Condition or disease Intervention/treatment Phase Solid Tumors Drug: RC48-ADC Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (...) ); Serious complications such as diabetes, interstitial pneumonia, pulmonary fibrosis, hypertension and Acute lung disease; Patients using trastuzumab in the 60 days before the experiments; Uncontrolled primary or metastatic tumor of brain; Current peripheral neuropathy of Grade ≥ 2; History of nerve or psychiatric disorders. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>